Exhibit 99.1 PRESS RELEASE Curis Provides Second Quarter 2025 Business Update Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., August 5, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its financial and operating results for the second quarter ended June 30, 2025. "We are pleased with our progress in the TakeAim Lymphoma study ...